Litcius/Paper detail

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Maura L. Gillison, Andy Trotti, Jonathan Harris, Avraham Eisbruch, Paul M. Harari, David J. Adelstein, Richard C. Jordan, Weiqiang Zhao, Erich M. Sturgis, Barbara Burtness, John A. Ridge, Jolie Ringash, James M. Galvin, Min Yao, Shlomo A. Koyfman, Dukagjin Blakaj, Mohammed A. Razaq, A. Dimitrios Colevas, Jonathan J. Beitler, Christopher U. Jones, Neal Dunlap, Samantha A. Seaward, Sharon A. Spencer, Thomas J. Galloway, Jack Phan, James J. Dignam, Quynh‐Thu Le

2018The Lancet1,300 citationsDOI

Topics & Concepts

CetuximabMedicineRadiation therapyInternal medicineOncologyCisplatinCancerChemotherapyColorectal cancerHead and Neck Cancer StudiesEsophageal Cancer Research and TreatmentColorectal and Anal Carcinomas
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial | Litcius